


## Caspase-8 (phospho Ser347) Polyclonal Antibody

|                              |   |
|------------------------------|---|
| <b>Catalog No :</b>          | YP0045  |
| <b>Reactivity :</b>          | Human;Rat   |
| <b>Applications :</b>        | WB;IHC;IF;ELISA   |
| <b>Target :</b>              | Caspase-8   |
| <b>Fields :</b>              | >>Platinum drug resistance;>>p53 signaling pathway;>>Apoptosis;>>Apoptosis - multiple species;>>Necroptosis;>>Toll-like receptor signaling pathway;>>NOD-like receptor signaling pathway;>>RIG-I-like receptor signaling pathway;>>C-type lectin receptor signaling pathway;>>IL-17 signaling pathway;>>TNF signaling pathway;>>Non-alcoholic fatty liver disease;>>Alcoholic liver disease;>>Alzheimer disease;>>Huntington disease;>>Pathways of neurodegeneration - multiple diseases;>>Pathogenic Escherichia coli infection;>>Salmonella infection;>>Legionellosis;>>Chagas disease;>>Toxoplasmosis;>>Tuberculosis;>>Hepatitis C;>>Hepatitis B;>>Measles;>>Human cytomegalovirus infection;>>Influenza A;>>Human papillomavirus infection;>>Kaposi sarcoma-associated herpesvirus infection;>>Herpes simplex virus 1 infection;>>Epstein-Barr virus infection;>>Human immunodeficiency virus 1 infection;>>Pathways in cancer;>>Viral carcinogenesis;>>Viral myocarditis;>>Lipid and atherosclerosis |
| <b>Gene Name :</b>           | CASP8   |
| <b>Protein Name :</b>        | Caspase8  |
| <b>Human Gene Id :</b>       | 841   |
| <b>Human Swiss Prot No :</b> | Q14790  |
| <b>Mouse Swiss Prot No :</b> | O89110  |
| <b>Immunogen :</b>           | The antiserum was produced against synthesized peptide derived from human Caspase 8 around the phosphorylation site of Ser347. AA range:313-362   |
| <b>Specificity :</b>         | Phospho-Caspase-8 (S347) Polyclonal Antibody detects endogenous levels of Caspase-8 protein only when phosphorylated at S347.   |
| <b>Formulation :</b>         | Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.   |


|                               |  |
|-------------------------------|--|
| <b>Source :</b>               | Polyclonal, Rabbit,IgG   |
| <b>Dilution :</b>             | WB 1:500 - 1:2000. IHC 1:100 - 1:300. ELISA: 1:5000.. IF 1:50-200  |
| <b>Purification :</b>         | The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.  |
| <b>Concentration :</b>        | 1 mg/ml  |
| <b>Storage Stability :</b>    | -15°C to -25°C/1 year(Do not lower than -25°C)   |
| <b>Observed Band :</b>        | 55kD   |
| <b>Cell Pathway :</b>         | p53;Apoptosis_Inhibition;Apoptosis_Mitochondrial;Apoptosis_Overview;Toll_Like;NOD-like receptor;RIG-I-like receptor;Alzheimer's disease;Huntington's disease;Pathways in cancer;Viral myocarditis;   |
| <b>Background :</b>           | This gene encodes a member of the cysteine-aspartic acid protease (caspase) family. Sequential activation of caspases plays a central role in the execution-phase of cell apoptosis. Caspases exist as inactive proenzymes composed of a prodomain, a large protease subunit, and a small protease subunit. Activation of caspases requires proteolytic processing at conserved internal aspartic residues to generate a heterodimeric enzyme consisting of the large and small subunits. This protein is involved in the programmed cell death induced by Fas and various apoptotic stimuli. The N-terminal FADD-like death effector domain of this protein suggests that it may interact with Fas-interacting protein FADD. This protein was detected in the insoluble fraction of the affected brain region from Huntington disease patients but not in those from normal controls, which implicated the role in neurodegenerative diseases. Many alt |
| <b>Function :</b>             | catalytic activity:Strict requirement for Asp at position P1 and has a preferred cleavage sequence of (Leu/Asp/Val)-Glu-Thr-Asp- -(Gly/Ser/Ala).,disease:Defects in CASP8 are the cause of caspase-8 deficiency (CASP8D) [MIM:607271]. CASP8D is a disorder resembling autoimmune lymphoproliferative syndrome (ALPS). It is characterized by lymphadenopathy, splenomegaly, and defective CD95-induced apoptosis of peripheral blood lymphocytes (PBLs). It leads to defects in activation of T-lymphocytes, B-lymphocytes, and natural killer cells leading to immunodeficiency characterized by recurrent sinopulmonary and herpes simplex virus infections and poor responses to immunization.,domain:Isoform 9 contains a N-terminal extension that is required for interaction with the BCAP31 complex.,function:Most upstream protease of the activation cascade of caspases responsible for the TNFRSF6/FAS mediated and TNF                     |
| <b>Subcellular Location :</b> | Cytoplasm . Nucleus .<br><br>Isoform 1, isoform 5 and isoform 7 are expressed in a wide variety of tissues.  |

|                        |   |
|------------------------|---|
| <b>Expression :</b>    | Highest expression in peripheral blood leukocytes, spleen, thymus and liver.<br>Barely detectable in brain, testis and skeletal muscle. |
| <b>Tag :</b>           | hot   |
| <b>Sort :</b>          | 3175  |
| <b>No4 :</b>           | 1   |
| <b>Host :</b>          | Rabbit  |
| <b>Modifications :</b> | Phospho   |

## Products Images



Immunohistochemistry analysis of paraffin-embedded human lung carcinoma, using Caspase 8 (Phospho-Ser347) Antibody. The picture on the right is blocked with the phospho peptide.



Western blot analysis of lysates from Jurkat cells, using Caspase 8 (Phospho-Ser347) Antibody. The lane on the right is blocked with the phospho peptide.